| Applications: |
Immunodepletion/Immunocompetition |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
CXCL5 Blocking Peptide for STJ506006 is synthetically produced from the 1-60 sequence and is suitable for use in western blot applications. |
| Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Gene Symbol: |
Cxcl5 |
| Gene ID: |
20311 |
| Uniprot ID: |
CXCL5_MOUSE |
| Immunogen Region: |
1-60 |
| Specificity: |
This blocking peptide is recommended for use in combination with CXCL5 antibody, STJ506006 |
| Immunogen: |
Synthetic peptide taken within amino acid region 1-60 on mouse C-X-C motif chemokine 5. |
| Post Translational Modifications | GCP-2(1-78) and GCP-2(9-78) are produced by proteolytic cleavage after secretion from fibroblasts and epithelial cells. GCP-2(9-78) is the most prominent form. A number of additional N-terminal (processed between pos. 41 and 48) and C-terminal (processed between pos. 118 and 132) processed forms have been identified, probably also representing intermediate states. |
| Function | May participate in the recruitment of inflammatory cells by injured or infected tissue. GCP-2(1-78) and, more potent, GCP-2(9-78) attract neutrophils and are involved in neutrophil activation. |
| Peptide Name | C-X-C Motif Chemokine 5Cytokine LixSmall-Inducible Cytokine B5 Cleaved Into - Gcp-2(1-78 - Gcp-2(9-78 |
| Database Links | Reactome: R-MMU-380108Reactome: -MMU-418594 |
| Cellular Localisation | Secreted |
| Alternative Peptide Names | C-X-C Motif Chemokine 5 proteinCytokine Lix proteinSmall-Inducible Cytokine B5 Cleaved Into - Gcp-2(1-78 - Gcp-2(9-78 proteinCxcl5 proteinScyb5 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
